Search results for "compounds"

showing 10 items of 3372 documents

Biomonitoring of bisphenols A, F, S in human milk and probabilistic risk assessment for breastfed infants

2019

The present study addresses the presence of bisphenols A (BPA) and its analogs bisphenol F (BPF) and S (BPS) in milk of 120 mothers living in Valencia (Spain) and participating in the BETTERMILK project (year 2015). We also studied the factors that could influence the BPA levels and estimated the exposure and the risk for breast fed infants. The frequency of detection of total (conjugated + unconjugated) and unconjugated-BPA were 83% and 77%. with a geometric mean of 0.29 ng/mL and 0.15 ng/mL, respectively. The frequency of detection was much lower for total-BPF (22%) and total-BPS (1.1%). The place of residence of the mother and the use of personal care products showed significant associat…

AdultTolerable daily intakeendocrine systemPercentileEnvironmental Engineering010504 meteorology & atmospheric sciencesBisphenol FBisphenolMothers010501 environmental sciences01 natural sciencesPhenolsEnvironmental healthBiomonitoringHumansEnvironmental ChemistryMedicineSulfonesBenzhydryl CompoundsWaste Management and DisposalRisk assessment0105 earth and related environmental sciencesMilk HumanProbabilistic risk assessmenturogenital systembusiness.industryHuman milkInfantBisphenolPollutionHuman biomonitoringBreast FeedingMaternal ExposureSpainEnvironmental PollutantsFemaleGeometric meanbusinessRisk assessmentInfantshormones hormone substitutes and hormone antagonistsEnvironmental MonitoringScience of The Total Environment
researchProduct

Increased DHEAs levels in PCO syndrome: evidence for the existence of two subgroups of patients

1986

In 49 patients affected by PCO syndrome the serum levels of dehydroepiandroster-one-sulphate (DHEAs) were determined and correlated with the cfinical presentation and the endocrine pattern. Twenty-three patients (47%) had high DHEAs levels (h-DHEAs patients). They presented a milder clinical presentation (low incidence of amenorrhea) than PCO patients with normal DHEAs levels (n-DHEAs patients). In h-DHEAs patients the finding of a normal DHEAs. response to ACTH and of slightly increased 17OHP serum levels suggested that the elevation of serum DHEAs was not due to an adrenal enzymatic deficiency but to a tonic hyperstimulation of the adrenals. Two subgroups of h-DHEAs patients were identifi…

Adultendocrine systemmedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismDehydroepiandrosteroneEstroneAdrenocorticotropic hormoneBiologychemistry.chemical_compoundEndocrinologyDehydroepiandrosterone sulfateAdrenocorticotropic HormoneInternal medicinepolycyclic compoundsmedicineHumansEndocrine systemskin and connective tissue diseasesAmenorrheaThyrotropin-Releasing HormoneDehydroepiandrosterone SulfateAdrenal glandHyperandrogenismDehydroepiandrosteronemedicine.diseasePolycystic ovaryProlactinmedicine.anatomical_structureEndocrinologychemistryFemalehuman activitieshormones hormone substitutes and hormone antagonistsPolycystic Ovary SyndromeJournal of Endocrinological Investigation
researchProduct

Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome

1995

Objective To reevaluate the clinical significance of elevations of adrenal androgens in polycystic ovary syndrome (PCOS). Methods Thirty women with PCOS and ten ovulatory controls were evaluated. Serum dehydroepiandrosterone (DHEA) sulfate and 11β-hydroxyandrostenedione were measured before and after 3 and 6 months of GnRH agonist (GnRH-A) therapy. All controls and 15 women with PCOS received intravenous ACTH before and after GnRH-A therapy. Results Twenty-one (70%) of the women with PCOS had elevations of DHEA sulfate, and 16 (53%) had elevations in 11/3-hydroxyandrostenedione. Only two women with PCOS had normal values of both adrenal androgens. After GnRH-A therapy, only 11 subjects (37%…

Adultendocrine systemmedicine.medical_specialtyendocrine system diseasesmedicine.drug_classDehydroepiandrosteroneOvaryPeptide hormonechemistry.chemical_compoundDehydroepiandrosterone sulfateAdrenocorticotropic HormoneInternal medicinepolycyclic compoundsmedicineHumansAndrostenedioneTriptorelin PamoateDehydroepiandrosterone Sulfatebusiness.industryAndrostenedioneObstetrics and GynecologyDehydroepiandrosteroneAndrogenPolycystic ovaryAndrogen secretionmedicine.anatomical_structureEndocrinologychemistryCase-Control StudiesFemaleLeuprolidebusinesshormones hormone substitutes and hormone antagonistsPolycystic Ovary SyndromeObstetrics & Gynecology
researchProduct

Evaluation of carpal tunnel syndrome in patients with polyneuropathy

1997

The difference between the median nerve latency to the second lumbrical muscle and the ulnar nerve latency to the second interosseous muscle (L-I DIFF) was tested in a prospective study to discriminate whether prolonged distal motor latency of the median nerve in patients with polyneuropathy (PNP) reflects an additional carpal tunnel syndrome (CTS). We investigated 92 patients (107 hands) with CTS, 30 patients (34 hands) with PNP, 22 patients (27 hands) with CTS and coexisting PNP (PNP+CTS), and 77 controls (87 hands). L-I DIFF was significantly prolonged in both the CTS and PNP+CTS patients as compared to PNP patients and controls. It proved to be the most specific test to differentiate be…

Adultinorganic chemicalsmedicine.medical_specialtyPhysiologyNeural ConductionNerve conduction velocityCellular and Molecular NeurosciencePhysiology (medical)medicineHumansheterocyclic compoundsIn patientNeurons AfferentProspective cohort studyUlnar nerveCarpal tunnel syndromeUlnar NerveAgedMotor Neuronsmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseCarpal Tunnel SyndromeMedian nerveMedian Nervenervous system diseasesSurgeryenzymes and coenzymes (carbohydrates)Evaluation Studies as TopicNerve conduction studyNeurology (clinical)businessPolyneuropathyDemyelinating DiseasesMuscle & Nerve
researchProduct

Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers

1993

Leflunomide (HWA 486), an isoxazol derivative, has been shown to be very effective in combating autoimmune diseases and transplantation rejection in a great number of animal models. The main metabolite of leflunomide, A77 1726, is a potent antiproliferative compound. To further elucidate this effect, lymphocytes of healthy human donors were cultured for 24, 48 or 72 h in the presence of PHA or immobilized anti-CD3 antibody. A77 1726 was added at concentrations between 10 and 100 microM. Flow cytometric evaluation of early activation or proliferation markers (IL-2 and transferrin receptors, respectively) showed that their expression was inhibited in a dose-dependent manner by A77 1726. Toget…

Adultmedicine.medical_specialtyAllergyToluidinesMetaboliteImmunologyHydroxybutyratesTransferrin receptorBiologyPharmacologyLymphocyte ActivationToxicologychemistry.chemical_compoundImmune systemInternal medicineNitrilesReceptors TransferrinmedicineHumansPharmacology (medical)PhytohemagglutininsLeflunomidePharmacologyAniline CompoundsAnti-Inflammatory Agents Non-SteroidalReceptors Interleukin-2Isoxazolesmedicine.diseaseRheumatologyTransplantationchemistryCrotonatesImmunologybiology.proteinAntibodyBiomarkersLeflunomidemedicine.drugAgents and Actions
researchProduct

Association between exposure to organochlorine compounds and maternal thyroid status: Role of the iodothyronine deiodinase 1 gene.

2017

Introduction: Exposure to organochlorine compounds (OCs) may interfere with thyroid hormone (TH) homeostasis. The disruption of the deiodinase (DIO) enzymes has been proposed as a mechanism of action. Aim: To evaluate the association between exposure to OCs and TH status in pregnant women, as well as to explore the role of genetic variations in the DIO1 and DIO2 genes. Methods: The study population (n = 1128) was composed of pregnant women who participated in the INMA Project (Spain, 2003–2006). Hexachlorobenzene (HCB), 1,1-dichloro-2,2-bis(4-chlorophenyl)ethylene (4,4´-DDE), b-hexachlorocyclohexane (b-HCH), polychlorobiphenyl (PCB) congeners 138, 153 and 180, thyroid stimulating hormone (T…

Adultmedicine.medical_specialtyDeiodinaseDIO2Thyrotropin010501 environmental sciences01 natural sciencesIodide Peroxidase03 medical and health sciences0302 clinical medicineThyroid-stimulating hormonePregnancyInternal medicinemedicineHydrocarbons ChlorinatedHumans030212 general & internal medicineDeiodinase enzymeslcsh:Environmental sciences0105 earth and related environmental sciencesGeneral Environmental Sciencelcsh:GE1-350ThyroidPregnancyTriiodothyroninebiologyChemistryThyroidOrganochlorine compoundsFetal developmentmedicine.diseaseDietPregnancy Trimester FirstThyroxinemedicine.anatomical_structureEndocrinologySpainbiology.proteinGestationTriiodothyronineFemaleHormoneEnvironment international
researchProduct

Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.

2007

ABSTRACT Background A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12 months. Patients and methods DTX, 75 mg/m2, was administered by 60 min i.v. infusion, followed by OXA, 100 mg/m2, given by a 2 h i.v., on day 1 every 21 days. Results From October 2003 to June 2006, 43 ovarian cancer patients were enrolled. Median PFI was 26 months. All patients were available for response evaluation: 17 complete responses and 12 partial responses were registered, for an overall response rate of 67.4%. The median response duration …

Adultmedicine.medical_specialtyOrganoplatinum CompoundsAnemiaSettore MED/06 - Oncologia MedicaOvarian cancer recurrencedocetaxel ovarian cancer recurrence oxaliplatinPhases of clinical researchDocetaxelGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedOvarian NeoplasmsLeukopeniabusiness.industryHematologyMiddle Agedmedicine.diseaseOxaliplatinSurgeryOxaliplatinRegimenTreatment OutcomeOncologyDocetaxelDocetaxel; Ovarian cancer recurrence; OxaliplatinToxicityFemaleTaxoidsmedicine.symptomNeoplasm Recurrence LocalOvarian cancerbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder

2012

Abstract Background β-Adrenoceptor agonists are effective in animal models of bladder dysfunction, and the human bladder primarily expresses the β3 receptor subtype. Objective To evaluate the efficacy and tolerability of the highly selective and potent β3-adrenoceptor agonist solabegron in a clinical proof-of-concept study in incontinent women with overactive bladder (OAB). Design, setting, and participants This was a randomized, double-blind trial in adult women with OAB (one or more 24-h incontinence episodes and eight or more average 24-h micturitions). Interventions Solabegron 50mg ( n =88), solabegron 125mg ( n =85), or placebo ( n =85)—all twice daily—were administered. Outcome measur…

Adultmedicine.medical_specialtyTime FactorsUrologymedia_common.quotation_subjectUrinary BladderArgentinaTaiwanPlacebo-controlled studyUrologyUrinationAdrenergic beta-3 Receptor AgonistsPlaceboBenzoatesUrinationDrug Administration ScheduleSouth AfricaYoung AdultSolabegronDouble-Blind MethodRepublic of KoreamedicineHumansAgedmedia_commonAniline CompoundsUrinary Bladder Overactivebusiness.industryBiphenyl CompoundsAustraliaMiddle Agedmedicine.diseaseEuropeUrodynamicsTreatment OutcomeUrinary IncontinenceBlood pressureOveractive bladderTolerabilityAmbulatoryLinear ModelsFemalebusinessNew Zealandmedicine.drugEuropean urology
researchProduct

Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies

2019

Ceftolozane-tazobactam (C/T), a novel fifth-generation cephalosporin/β-lactamase inhibitor combination active against multidrug-resistant (MDR) Pseudomonas aeruginosa, is currently approved by the U.S. Food and Drug Administration (FDA) to treat complicated intra-abdominal and urinary tract

Adultmedicine.medical_specialtymedicine.drug_classCritical IllnessUrinary systemCephalosporinHemodiafiltrationMicrobial Sensitivity TestsOff-label usemedicine.disease_causeExtracorporealPharmacokineticspolycyclic compoundsmedicineHumansPseudomonas InfectionsPharmacology (medical)Intensive care medicineLetter to the EditorPharmacologyCritically illbusiness.industryPseudomonas aeruginosaPrecursor Cell Lymphoblastic Leukemia-Lymphomabacterial infections and mycosesAnti-Bacterial AgentsCephalosporinsInfectious DiseasesPseudomonas aeruginosaFemaleCeftolozanebusinessAntimicrobial Agents and Chemotherapy
researchProduct

Occupational hygiene in terms of volatile organic compounds (VOCs) and bioaerosols at two solid waste management plants in Finland

2012

Abstract Factors affecting occupational hygiene were measured at the solid waste transferring plant at Hyvinkaa and at the optic separation plant in Hameenlinna. Measurements consisted of volatile organic compounds (VOCs) and bioaerosols including microbes, dust and endotoxins. The most abundant compounds in both of the plants were aliphatic and aromatic hydrocarbons, esters of carboxylic acids, ketones and terpenes. In terms of odour generation, the most important emissions were acetic acid, 2,3-butanedione, ethyl acetate, alpha-pinene and limonene due to their low threshold odour concentrations. At the optic waste separation plant, limonene occurred at the highest concentration of all sin…

Aerosolschemistry.chemical_classificationVolatile Organic CompoundsLimoneneMunicipal solid wasteIndoor bioaerosolta1172Ethyl acetateTerpenechemistry.chemical_compoundWaste treatmentWaste ManagementchemistryOccupational ExposureEnvironmental chemistryOdorantsVolatile organic compoundOccupational exposure limitWaste Management and DisposalFinlandWaste Management
researchProduct